Form 4: Acadia Pharmaceuticals Exec Sells Stock
Statement of Changes in Beneficial Ownership
Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals Inc., reported transactions involving the sale of company stock.
Summary
- Mark C. Schneyer, Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc., engaged in stock transactions on April 5, 2026, and April 7, 2026.
- On April 5, 2026, 5,276 shares of common stock were acquired, with the transaction code 'M' indicating a disposition.
- Following this transaction, 65,545 shares of common stock were beneficially owned.
- On April 7, 2026, an additional 2,709 shares were disposed of at a price of $22.2 per share, transaction code 'S'.
- After the April 7th transaction, the beneficial ownership of common stock was 62,836 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider stock transactions related to tax obligations and vesting schedules, without indicating significant positive or negative company performance.
Negatives
- Mark C. Schneyer disposed of 2,709 shares of common stock on April 7, 2026, at a price of $22.2 per share.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently signal company performance, but rather individual executive trading activity.
Key Dates
| Date | Description |
|---|---|
| 04/05/2023 | Vesting of restricted stock units begins in four equal annual installments. |
| 04/05/2026 | Earliest transaction date reported; acquisition of 5,276 restricted stock units. |
| 04/07/2026 | Sale of 2,709 shares of common stock. |
Keywords
Acadia Pharmaceuticals, ACAD, Form 4, Stock Transaction, Insider Trading, Beneficial Ownership, Mark C. Schneyer, EVP, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.